Study S001033

Semaglutide and Dapagliflozin in Diabetic Patients With Different Pathophysiology

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT04451837
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: NONE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 200
Start: 2020-09-10
Primary completion: 2021-12-15
Lead sponsor: Region Skane
Conditions: Type2 Diabetes
Interventions: DRUG:Semaglutide; DRUG:Dapagliflozin
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Hba1c [6 months]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0007799	Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology. Dwibedi C, Nature metabolism	2024	Randomized trial	PMID 38177805 DOI	cites ClinicalTrials.gov:NCT04451837; registry reference DERIVED:38177805